*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| C866 - Primary cutaneous CD30-positive T-cell proliferations - as a primary diagnosis code | C866 - Primary cutaneous CD30-positive T-cell proliferations - as a primary or secondary diagnosis code | |
|---|---|---|
| OUTCOMES | ||
| Avg. LOS | 6.95 | |
| Readmission Rate (%) | 27.82 | |
| Unplanned Readmission Rate (%) | 38.24 | |
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) | ||
| PAYMENTS AND CHARGES | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| MARKET SIZING & INCIDENCE RATES | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations after Exclusion | ||
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 841: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH COMPLICATION OR COMORBIDITY (CC) | |
|---|---|
| Total Hospitalizations at DRG | 25,646 |
| Total Hospitalizations with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | 21 |
| DRG Share of Total Hospitalizations | 0.08 |
| % of Total ICD C866 - Primary cutaneous CD30-positive T-cell proliferations in DRG | 51.22 |
| Avg LOS at DRG | 5.67 |
| Avg LOS with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | 7.52 |
| Readmission Rate at DRG | 36.28 |
| Readmission Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | 52.38 |
| Unplanned Readmission Rate at DRG | 22.95 |
| Unplanned Readmission Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | NA |
| Total Medicare payments at DRG | $299,718,477 |
| Total Medicare payments with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $247,837 |
| Total Medicare payment per Day at DRG | $2,062 |
| Total Medicare payment per Day with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $1,569 |
| Total Medicare payment per Hospitalization at DRG | $11,687 |
| Total Medicare payment per Hospitalization with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $11,802 |
| Total Medicare Charges at DRG | $1,432,739,779 |
| Total Medicare Charges with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $1,271,033 |
| Avg Charges at DRG | $55,866 |
| Avg Charges with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $60,525 |
| Mortality Rate at DRG | 2.6 |
| Mortality Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | NA |
| SNF Discharge Rate at DRG | 13.23 |
| SNF Discharge Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | NA |
| Home Discharge Rate at DRG | 49.84 |
| Home Discharge Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | NA |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 841: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH COMPLICATION OR COMORBIDITY (CC) | DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|
| Total Hospitalizations at DRG | 25,646 | |
| Total Hospitalizations with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | 23 | |
| DRG Share of Total Hospitalizations | 0.08 | |
| % of Total ICD C866 - Primary cutaneous CD30-positive T-cell proliferations in DRG | 7.1 | |
| Avg LOS at DRG | 5.67 | |
| Avg LOS with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | 7.57 | |
| Readmission Rate at DRG | 36.28 | |
| Readmission Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | 52.17 | |
| Unplanned Readmission Rate at DRG | 22.95 | |
| Unplanned Readmission Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | 47.83 | |
| Total Medicare payments at DRG | $299,718,477 | |
| Total Medicare payments with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $294,555 | |
| Total Medicare payment per Day at DRG | $2,062 | |
| Total Medicare payment per Day with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $1,693 | |
| Total Medicare payment per Hospitalization at DRG | $11,687 | |
| Total Medicare payment per Hospitalization with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $12,807 | |
| Total Medicare Charges at DRG | $1,432,739,779 | |
| Total Medicare Charges with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $1,495,634 | |
| Avg Charges at DRG | $55,866 | |
| Avg Charges with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | $65,028 | |
| Mortality Rate at DRG | 2.6 | |
| Mortality Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | NA | |
| SNF Discharge Rate at DRG | 13.23 | |
| SNF Discharge Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | NA | |
| Home Discharge Rate at DRG | 49.84 | |
| Home Discharge Rate with ICD C866 - Primary cutaneous CD30-positive T-cell proliferations | NA |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| MEMORIAL SLOAN KETTERING CANCER CENTER | 1275 YORK AVE | NEW YORK | NY | 10065 | 12 |